Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stakeholders Warn Comparative Effectiveness Research Is No Magic Bullet

This article was originally published in The Gray Sheet

Executive Summary

As Congress moves closer to approving significant funding for comparative effectiveness programs, questions remain over how to structure a sustainable system for conducting the research and how to avoid unintended consequences in sharing the data

You may also be interested in...



Comparative Effectiveness Researchers Look Beyond Randomized Trials

Researchers awaiting guidance from the Administration on how it will allocate $1.1 billion in stimulus funds for comparative effectiveness research are exploring ways to include alternatives to randomized clinical trials in gathering evidence to inform health care decisions

Comparative Effectiveness Researchers Look Beyond Randomized Trials

Researchers awaiting guidance from the Administration on how it will allocate $1.1 billion in stimulus funds for comparative effectiveness research are exploring ways to include alternatives to randomized clinical trials in gathering evidence to inform health care decisions

CMS Coverage Director Steve Phurrough Will Move To AHRQ Outcomes Office

The Agency for Healthcare Research and Quality is already bolstering its capabilities in research on the comparative effectiveness of medical services with the addition of CMS official Steve Phurrough

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027044

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel